Alethia Biotherapeutics Inc.

Alethia is developing innovative therapeutic approaches in areas of unmet medical needs, capitalizing on its capacity to identify and validate disease-specific targets for the development of highly focused monoclonal antibody-based therapeutics. The company is currently focusing on cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss.